- Home
- NBXG vs WVE Comparison
NBXG vs WVE Comparison
Compare NBXG & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBXG
- WVE
- Stock Information
- Founded
- NBXG 2021
- WVE 2012
- Country
- NBXG United States
- WVE Singapore
- Employees
- NBXG N/A
- WVE N/A
- Industry
- NBXG Trusts Except Educational Religious and Charitable
- WVE Biotechnology: Pharmaceutical Preparations
- Sector
- NBXG Finance
- WVE Health Care
- Exchange
- NBXG Nasdaq
- WVE Nasdaq
- Market Cap
- NBXG 1.1B
- WVE 915.6M
- IPO Year
- NBXG N/A
- WVE 2015
- Fundamental
- Price
- NBXG $14.68
- WVE $10.15
- Analyst Decision
- NBXG
- WVE Strong Buy
- Analyst Count
- NBXG 0
- WVE 16
- Target Price
- NBXG N/A
- WVE $20.00
- AVG Volume (30 Days)
- NBXG 243.7K
- WVE 1.6M
- Earning Date
- NBXG 01-01-0001
- WVE 07-30-2025
- Dividend Yield
- NBXG 10.25%
- WVE N/A
- EPS Growth
- NBXG N/A
- WVE N/A
- EPS
- NBXG N/A
- WVE N/A
- Revenue
- NBXG N/A
- WVE $93,946,000.00
- Revenue This Year
- NBXG N/A
- WVE N/A
- Revenue Next Year
- NBXG N/A
- WVE $4.55
- P/E Ratio
- NBXG N/A
- WVE N/A
- Revenue Growth
- NBXG N/A
- WVE N/A
- 52 Week Low
- NBXG $9.31
- WVE $5.04
- 52 Week High
- NBXG $12.23
- WVE $16.74
- Technical
- Relative Strength Index (RSI)
- NBXG 51.27
- WVE 72.29
- Support Level
- NBXG $14.39
- WVE $9.26
- Resistance Level
- NBXG $14.95
- WVE $9.93
- Average True Range (ATR)
- NBXG 0.18
- WVE 0.50
- MACD
- NBXG -0.05
- WVE 0.11
- Stochastic Oscillator
- NBXG 48.74
- WVE 84.68
About NBXG Neuberger Berman Next Generation Connectivity Fund Inc.
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. companies, in any market capitalization range, that is relevant to the theme of investing in "NextGen Companies".
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.